Zoetis (ZTS) Competitors

AbbVie (NYSE:ABBV) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.

Which has preferable earnings & valuation, ABBV or ZTS?

AbbVie has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$55B	6.21	$4.86B	$3.37	57.41
Zoetis	$8.92B	9.86	$2.34B	$5.19	37.13

Does the media prefer ABBV or ZTS?

In the previous week, AbbVie had 8 more articles in the media than Zoetis. MarketBeat recorded 22 mentions for AbbVie and 14 mentions for Zoetis. AbbVie's average media sentiment score of 0.62 beat Zoetis' score of 0.56 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	10 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Zoetis	9 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ABBV or ZTS a better dividend stock?

AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.2%. Zoetis pays an annual dividend of $1.72 per share and has a dividend yield of 0.9%. AbbVie pays out 184.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis pays out 33.1% of its earnings in the form of a dividend. AbbVie has increased its dividend for 52 consecutive years and Zoetis has increased its dividend for 13 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Does the MarketBeat Community believe in ABBV or ZTS?

AbbVie received 413 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.95% of users gave Zoetis an outperform vote while only 73.34% of users gave AbbVie an outperform vote.

Company	Underperform	Outperform
AbbVie	Outperform Votes 1318 73.34%	Underperform Votes 479 26.66%
Zoetis	Outperform Votes 905 77.95%	Underperform Votes 256 22.05%

Do analysts recommend ABBV or ZTS?

AbbVie presently has a consensus target price of $191.64, suggesting a potential downside of 0.87%. Zoetis has a consensus target price of $220.38, suggesting a potential upside of 14.34%. Given Zoetis' stronger consensus rating and higher probable upside, analysts plainly believe Zoetis is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Zoetis	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11

Do institutionals & insiders believe in ABBV or ZTS?

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 0.3% of AbbVie shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is ABBV or ZTS more profitable?

Zoetis has a net margin of 26.29% compared to AbbVie's net margin of 9.71%. AbbVie's return on equity of 203.66% beat Zoetis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.71%	203.66%	13.56%
Zoetis	26.29%	50.67%	17.88%

Which has more volatility & risk, ABBV or ZTS?

AbbVie has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Summary

AbbVie beats Zoetis on 11 of the 21 factors compared between the two stocks.